Dr Georg Winter

Georg Winter, PhD, performed his graduate studies at CeMM, working on elucidating the mechanism of action of cancer drugs. He specialized on proteomics, as well as chemical genetics approaches. He continued his training in chemical biology, working as a postdoctoral fellow with Dr. James Bradner the Dana Farber Cancer Institute. Supported by an EMBO fellowship, he published the first paper reporting on in vivo target protein degradation (Winter et al., Science 2015). He was recruited as a CeMM Principal Investigator in June 2016. Thematically, his lab works at the interface of chemical biology, cancer, and gene control. His group aims to innovate novel pharmacologic strategies that allow us to probe, understand and eventually disrupt aberrant transcriptional circuits in cancer. 

Dr. Winter’s research strategy is inspired and driven by high-throughput and unbiased technologies such as quantitative proteomics, (nascent) transcriptomics and functional genomics. Connecting these technologies with synthetic chemistry empowers the understanding of the mechanism of action of proteins, protein complexes or small molecules both on a holistic but also mechanistic level.  

Dr. Winter’s research has led to the incorporation of C4 Therapeutics, moreover, he is a scientific co-founder of Proxygen and Solgate Therapeutics. His group is supported by several national and international grants and fellowships including an ERC Starting Grant and an Aspire Award from the Mark Foundation. Dr. Winter’s contributions to the field of targeted protein degradation were acknowledged via multiple prices and awards, including the Tetrahedron Young Investigator Award, the EFMC Prize for Young Chemical Biologist in Academia, the German Lectureship for Chemical Biology, the Wilson S. Stone Memorial Award from MD Anderson, the Eppendorf Award for European Scientists, and the Elisabeth Lutz Award of the Austrian Academy of Sciences.